Moleculin Biotech P/E 2024

Moleculin Biotech Aktienanalyse

What does Moleculin Biotech do?

Moleculin Biotech Inc is a biopharmaceutical company based in Houston, Texas, that focuses on the development of innovative cancer therapies. The company was founded in 2015 and has since made significant progress in the research and development of drugs for the treatment of cancer. The company follows an innovative business model consisting of two main divisions: research and development, as well as distribution. Moleculin Biotech focuses on identifying compounds that target specific types and stages of cancer in order to enable personalized cancer treatment. The company currently has several projects in the pipeline, each with the potential to change the way cancer is treated. In the research department, Moleculin Biotech focuses on identifying compounds that target cancer types that have been difficult to treat. The company is dedicated to developing effective drugs that can inhibit cell division in certain types of cancer and stop their growth. The critical goal is to develop medications that selectively attack cancer cells without affecting healthy cells. The distribution department of Moleculin Biotech is responsible for marketing and distributing the developed drugs. The company has a well-established network of distribution partners and agencies that help with the introduction of new products. Moleculin Biotech aims to distribute its products worldwide and continuously expand its patient base. One of Moleculin Biotech's key products is the compound WP1122. This molecule is a prodrug capable of selectively accumulating and acting in cancer cells. As a result, it can be used in combination with other cancer therapies to increase treatment efficacy. The company has already demonstrated the potential of WP1122 in clinical trials and is currently working on its market launch. Another significant product of Moleculin Biotech is Annamycin. This is a chemotherapeutic specifically developed for the treatment of leukemia. The medication has already been tested in clinical trials and proven to be effective. Annamycin has the potential to dramatically change and improve the treatment of leukemia. In addition to these two products, Moleculin Biotech also has MSP-2017 in its portfolio. This anti-tumor drug specifically targets pancreatic cancer and has the potential to increase the survival rate of patients in advanced stages of the disease. MSP-2017 is currently still in the development phase and is expected to enter the market in the coming years. Overall, Moleculin Biotech is a promising company focusing on the development of innovative cancer therapies. The company has the potential to fundamentally change cancer treatment and save the lives of millions of people worldwide. The company is committed to intensifying its research and development activities and continuously expanding its product pipeline. Moleculin Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Moleculin Biotech's P/E Ratio

The Price to Earnings (P/E) Ratio of Moleculin Biotech is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Moleculin Biotech's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Moleculin Biotech is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Moleculin Biotech’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Moleculin Biotech stock

What is the price-to-earnings ratio of Moleculin Biotech?

The price-earnings ratio of Moleculin Biotech is currently -0.47.

How has the price-earnings ratio of Moleculin Biotech changed compared to last year?

The price-to-earnings ratio of Moleculin Biotech has increased by -17.54% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Moleculin Biotech high compared to other companies?

Yes, the price-to-earnings ratio of Moleculin Biotech is high compared to other companies.

How does an increase in the price-earnings ratio of Moleculin Biotech affect the company?

An increase in the price-earnings ratio of Moleculin Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Moleculin Biotech affect the company?

A decrease in the price-earnings ratio of Moleculin Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Moleculin Biotech?

Some factors that influence the price-earnings ratio of Moleculin Biotech are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Moleculin Biotech pay?

Over the past 12 months, Moleculin Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Moleculin Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Moleculin Biotech?

The current dividend yield of Moleculin Biotech is .

When does Moleculin Biotech pay dividends?

Moleculin Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Moleculin Biotech?

Moleculin Biotech paid dividends every year for the past 0 years.

What is the dividend of Moleculin Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Moleculin Biotech located?

Moleculin Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Moleculin Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Moleculin Biotech from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Moleculin Biotech pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Moleculin Biotech in the year 2023?

In the year 2023, Moleculin Biotech distributed 0 USD as dividends.

In which currency does Moleculin Biotech pay out the dividend?

The dividends of Moleculin Biotech are distributed in USD.